Sale of ranitidine continues despite U.S. FDA warning

No intimation from DGCI to stop sale of ranitidine-based drugs, says State FDA official; govt. hospitals asked to stop use

October 09, 2019 12:54 am | Updated 12:54 am IST - Mumbai

The U.S. FDA has issued an alert that ranitidine, including drugs with brand name Zantac, contain low levels of NDMA.

The U.S. FDA has issued an alert that ranitidine, including drugs with brand name Zantac, contain low levels of NDMA.

Following a U.S. Food and Drug Administration (FDA) warning about the presence of low levels of carcinogens in commonly used anti-acidity drug ranitidine, the Maharashtra Directorate of Health Services (DHS) has issued a circular to stop its use in government hospitals. However, the sale of ranitidine continues in chemist shops across the State.

On September 13, the U.S. FDA issued an alert for patients and healthcare professionals stating that ranitidine medicines, including some products commonly known by the brand name Zantac, contain low levels of a nitrosamine impurity called N-nitrosodimethylamine (NDMA). “NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests,” it said. The FDA is evaluating whether the low levels of NDMA in ranitidine pose a risk to patients and it will post that information when it is available.

Maharashtra FDA Assistant Commissioner (Drugs) D.R. Gahane said there was no intimation from the Drug Controller General of India to stop the sale of ranitidine-based drugs. “The Schedule H drug is available as oral tablets and injections under multiple brand names, the most popular being Rantac and Zinetac. We have collected samples of multiple brands and sent them for tests,” said Mr. Gahane.

Ranitidine is an H2 (histamine-2) blocker, which decreases the amount of acid created by the stomach. It is also prescribed for ulcers of stomach and intestines, gastroesophageal reflux disease etc. While the U.S. FDA has not suggested stopping the use of ranitidine, it issued an alert so that patients and doctors can make an informed choice and opt for other molecules that have similar use as ranitidine, if needed.

According to Hakim Kapasi, president of the North West Chemists Association in Mumbai, GlaxoSmithKline Pharmaceuticals Ltd. has voluntarily recalled stocks but the sale of other ranitidine-based drugs is on. “Without any instruction from the FDA, chemists will continue to sell,” said Mr. Kapasi.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.